Benefits of inpatient initiation of β-blockers

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 944-950

  Ventura, Hector O ^a,b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b New Orleans LA 70121 USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ISOPRENALINE; METOPROLOL;

ARTICLE; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSPNEA; FATIGUE; FLUID RETENTION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; PHYSICIAN; PRIORITY JOURNAL; REDUCTION; TITRIMETRY; TREATMENT CONTRAINDICATION;

ADRENERGIC BETA-ANTAGONISTS; DEATH, SUDDEN; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RECURRENCE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 10644286403     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.05.038     Document Type: Article

References (42)

1. Heart Failure Society of America. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail. 5:1999;357-382
2. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at: http:// www.acc.org/clinical/guidelines/nov96/1999/idex.htm. Accessed March 14, 2002
3. Frishman W.H., Lazar E.J. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol. 66:1990;66-70G
4. Packer M., Cohn J. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 83:1999;1-38A
5. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497
6. Herlitz J., Dellborg M., Karlson B.W., et al. Changes in the use of medications after acute myocardial infarction possible impact on mortality after myocardial infarction and long-term outcome. Coron Artery Dis. 12:2001;61-67
7. Spencer F., Scleparis G., Goldberg R.J., et al. Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction a community-wide perspective. Am Heart J. 142:2001;594-603
8. Krumholz H.M., Radford M.J., Wang Y., et al. Early β-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med. 131:1999;648-654
9. Petersen L.A., Normand S.-L.T., Leape L.L., et al. Comparison of use of medications after acute myocardial infarction in the Veterans Health Administration and Medicare. Circulation. 104:2001;2898-2904
10. Bart B.A., Ertl G., Held P., et al. Contemporary management of patients with left ventricular systolic dysfunction results from the SPICE Registry. Eur Heart J. 20:1999;1182-1190
11. Califf R.M., O'Connor C.M. β-blocker therapy for heart failure the evidence is in, now the work begins. [editorial] JAMA. 283:2000;1335-1337
12. Shivkumar K., Schultz L., Goldstein S., et al. Effects of propranolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. Am Heart J. 135:1998;261-267
13. Hanes D.S., Weir M.R. The β-blockers are they as protective in hypertension as in other cardiovascular conditions? J Clin Hypertens. 3:2001;236-243
14. Maggioni A.P., Latini R. How to use ACE inhibitors, β-blockers, and newer therapies in AMI. Am Heart J. 138:1999;S183-187
15. Basu S., Senior R., Raval U., et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction a placebo-controlled, randomized trial. Circulation. 96:1997;183-191
16. Chen J., Marciniak T.A., Radford M.J., et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients results from the national Cooperative Cardiovascular Project. J Am Coll Cardiol. 34:1999;1388-1394
17. Spargias K.S., Hall A.S., Greenwood D.C., et al. β-blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction evidence from the AIRE study. Heart. 81:1999;25-32
18. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 320:1989;618-627
19. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction ISIS-1. Lancet. 2:1986;57-66
20. MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). Am J Cardiol. 56:1985;1-57G
21. Yusuf S., Wittes J., Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 260:1988;2088-2093
22. Yusuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371
23. Herlitz J., Waagstein F., Lindqvist J., et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial). Am J Cardiol. 80:1997;. 40-4J
24. Roberts R., Rogers W.J., Muller H.S., et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation. 83:1991;422-437
25. Van de Werf F., Janssens L., Brzostek T., et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 22:1993;407-416
26. Dargie H., Colucci W., Ford I., et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomized trial. Lancet. 357:2001;1385-1390
27. Jánosi A., Ghali J.K., Herlitz J., et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure experiences from MERIT-HF. Am Heart J. 146:2003;721-728
28. Smith S.C., Blair S.N., Bonow R.O., et al. ACC/AHA guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 104:2001;1577-1579
29. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007
30. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) a randomised trial. Lancet. 353:1999;9-13
31. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658
32. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667
33. Hjalmarson Å., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 283:2000;1295-1302
34. Goldstein S., Fagerberg B., Hjalmarson Å., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. 38:2001;932-938
35. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Heart Lung Transplant. 21:2002;189-203
36. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET) randomized controlled trial. Lancet. 362:2003;7-13
37. Hjalmarson Å., Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet. 363:2003;1077
38. Whellan D.J., Gaulden L., Gattis W.A., et al. The benefit of implementing a heart failure disease management program. Arch Intern Med. 161:2001;2223-2228
39. Bradley E.H., Holmboe E.S., Mattera J.A., et al. A qualitative study of increasing β-blocker use after myocardial infarction why do some hospitals succeed? JAMA. 285:2001;2604-2611
40. Butler J., Arbogast P.G., BeLue R., et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 40:2002;1589-1595
41. Gheorghiade M., Gattis W.A., Lukas M.A., et al. Rationale and design of the Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. Am Heart J. 145:(Suppl):2003;S60-61
42. Gheorghiade M., Gattis W.A., Gallup D.S., et al. Pre-discharge initiation of carvedilol in patients stabilized during an admission for decompensated heart failure is a safe and effective strategy to improve the use of beta-blocker therapy results of the IMPACT-HF trial. J Cardiac Failure. 9:(Suppl):2003;S59